Table 3.
Lymphocyte subsets for predicting therapy response to anti-tumor necrosis factor agents.
| Lymphocyte subsets | Samples | Participants | Biologics | Definition of response | Predictive value | References |
|---|---|---|---|---|---|---|
| Transmembrane TNF-α bearing lymphocytes | Blood at baseline | 34 CD, 13 UC | IFX | Endoscopic response | For mean fluorescence intensity, AUC: 0.827 (95% CI, 0.695–0.960; P<0.001) | Amini et al. (23) |
| CD4+CD45RO cells | Blood at baseline | 16 CD | IFX/ADA | Clinical response | AUC: 1.0 (P = 0.03) | Dulic et al. (22) |
| CD4+HLADR cells | Blood at baseline | 16 CD | IFX/ADA | Clinical response | Pearson’s r: 0.50 (P = 0.058) | Dulic et al. (22) |
| CD4+ cells | Blood at baseline | 16 UC | IFX/ADA | Clinical response | AUC: 0.85 (P= 0.08) | Dulic et al. (22) |
| Th2 cells | Blood at baseline | 16 UC | IFX/ADA | Clinical response | Pearson’s r: 0.59 (P = 0.03) | Dulic et al. (22) |
| Th17 cells | Blood at baseline | 16 UC | IFX/ADA | Clinical response | Pearson’s r: 0.61 (P = 0.03) | Dulic et al. (22) |
| CD8+HLADR cells | Blood at baseline | 16 UC | IFX/ADA | Clinical response | Pearson’s r: 0.59 (P = 0.06) | Dulic et al. (22) |
| Treg cells | Blood at baseline | 20 CD | IFX | Clinical response | The mean percentage of Treg was lower in responders than non-responders (2.6% ± 1.1 vs. 7.3% ± 1.8; P < 0.0001) | Di Sabatino et al. (20) |
| Treg cells | Blood at baseline | 26 CD | ADA | Clinical response | The mean percentage of Treg was higher in responders than non-responders (4.0% [IQR 3.9–4.1%] vs. 5.1% [IQR 4.6–6.4%]; P =0.005) | Dige et al. (16) |
| Treg cells | Blood at baseline | 40 IBD | IFX | Clinical response | AUC: 0.82 (P = 0.0001) | Li et al. (21) |
| CD45RA+Foxp3lo resting Treg cells | Blood at baseline | 40 IBD | IFX | Clinical response | AUC: 0.81 (P = 0.001) | Li et al. (21) |
| CD45RA-Foxp3hi-activated Treg cells | Blood at baseline | 40 IBD | IFX | Clinical response | AUC:0.74 (P = 0.015) | Li et al. (21) |
| Type 1 regulatory-like T cells | Blood at baseline | 40 IBD | IFX | Clinical response | AUC: 0.73 (P = 0.02) | Li et al. (21) |
| CD25+CD4+ T cells | Blood at week 2 and baseline | 34 UC | IFX | Clinical response | AUC: 0.92 | Magnusson et al. (17) |
| CD25+CD8+ T cells | Blood at week 2 and baseline | 34 UC | IFX | Clinical response | AUC: 0.91 | Magnusson et al. (17) |
| Plasma cells | Biopsy at baseline | 72 IBD | IFX | Clinical and/or endoscopic improvement | Exploring cohort: AUC=0.81 External validation cohort: AUC=0.74 |
Gaujoux et al. (18) |
| GIMATS (IgG plasma cells, inflammatory mononuclear phagocytes, activated T cells, and stromal cells) | Biopsy at baseline | 139 IBD | IFX/ADA | Endoscopic response | Microarray dataset: AUC = 0.853 (95%CI: 0.778-0.928) RNA-seq dataset: AUC = 0.720 (95%CI: 0.559-0.881) |
Shi et al. (19) |
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; IQR, interquartile range; Treg cell, regulatory T cell; HLADR, human leukocyte antigen DR; IFX, infliximab; ADA, adalimumab.